Last reviewed · How we verify
A Study to Learn About Abrocitinib Tablets in People With Atopic Dermatitis in India
The purpose of this clinical trial is to learn about the safety and how well the study medicine (called Abrocitinib) works for the potential treatment of moderate to severe Atopic Dermatitis (AD) in India. AD, also known as atopic eczema, is a chronic, relapsing skin condition characterized by dry, itchy skin lesions which can affect any part of the body. Adult peoples who participate in this study will take either 100 mg or 200 mg of abrocitinib tablets by mouth for a duration of 12 weeks and adolescents will take for duration of 52 weeks. Knee Magnetic Resonance Imagine (MRI) will be done on adolescent peoples to determine bone safety findings. We will examine the experiences of people receiving the study medicines. This will help us determine if the study medicines are safe and how well they work.
Details
| Lead sponsor | Pfizer |
|---|---|
| Phase | PHASE3 |
| Status | COMPLETED |
| Enrolment | 200 |
| Start date | Sat Jul 16 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Thu Mar 14 2024 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Atopic Dermatitis
Interventions
- Abrocitinib 100 mg
- Abrocitinib 200 mg
Countries
India